From the Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong, China (Drs. Li, Sheng, and Lau); Division of Neurology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China (Drs. Kwan, Leung, Yu, and Hui); Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China (Dr. Tsoi).
Topiramate for Migraine Prophylaxis Among Chinese Population
Version of Record online: 13 APR 2007
Headache: The Journal of Head and Face Pain
Volume 47, Issue 4, pages 616–619, April 2007
How to Cite
Li, H. L., Kwan, P., Leung, H., Yu, E., Tsoi, T. H., Hui, A. C. F., Sheng, B. and Lau, K. K. (2007), Topiramate for Migraine Prophylaxis Among Chinese Population. Headache: The Journal of Head and Face Pain, 47: 616–619. doi: 10.1111/j.1526-4610.2007.00763_3.x
- Issue online: 13 APR 2007
- Version of Record online: 13 APR 2007
- Accepted for publication December 20, 2006.
We evaluated the efficacy and safety of topiramate for migraine prophylaxis among Chinese patients in a multicenter prospective observational study. We found that topiramate at low doses was effective in preventing migraine headache in Chinese patients and was generally well tolerated. There was no difference in baseline headache frequency or intensity between responders and nonresponders.